(Q33600521)

28 July 2017

Phase I study of oral lenalidomide in patients with refractory metastatic cancer (English)

1 reference

28 July 2017

Jeanny B Aragon-Ching

object named as

Jeanny B Aragon-Ching

William Douglas Figg, Sr.

2

0 references

9

object named as

William D Figg

1 reference

28 July 2017

1

William L Dahut

1 reference

28 July 2017

Sukyung Woo

3

1 reference

28 July 2017

Tanyifor M Tohnya

4

1 reference

28 July 2017

James L Gulley

5

1 reference

28 July 2017

Philip M Arlen

6

1 reference

28 July 2017

John J Wright

7

1 reference

28 July 2017

Jurgen Ventiz

8

1 reference

28 July 2017

1 June 2009

1 reference

The Journal of Clinical Pharmacology

28 July 2017

1 reference

28 July 2017

49

1 reference

28 July 2017

650-660

1 reference

28 July 2017

6

1 reference

Lenalidomide for the treatment of B-cell malignancies

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808857

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808857

Efficacy of lenalidomide in myelodysplastic syndromes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808857

Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808857

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808857

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808857

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808857

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808857

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808857

Antitumor activity of thalidomide in refractory multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808857

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808857

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808857

Thalidomide is an inhibitor of angiogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808857

Prediction of creatinine clearance from serum creatinine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808857

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

21 June 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009335001

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009335001

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009335001

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009335001

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009335001

Thalidomide dose proportionality assessment following single doses to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009335001

Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009335001

Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808857

Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19451403

12 December 2020

inferred from PubMed ID database lookup

The Vascularization of Tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19451403

12 December 2020

inferred from PubMed ID database lookup

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19451403

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1177/0091270009335001

1 reference

release_3pc7bypqkvb2tbkfw7gambngqy

28 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3pc7bypqkvb2tbkfw7gambngqy

24 November 2022

mapped directly with Wikidata item

PMCID

2808857

1 reference

28 July 2017

1 reference